Literature DB >> 8257291

Interleukin-1 production and cell-activation response to cytomegalovirus infection of vascular endothelial cells.

S B Woodroffe1, H M Garnett, V A Danis.   

Abstract

Human cytomegalovirus (HCMV) is a source of major complications in immunosuppressed individuals, and endothelial involvement in HCMV infection is well documented. Traditionally laboratory strains of HCMV have been used in experimental investigations in vitro; however the continuous propagation of these strains in fibroblasts have attenuated the virus making it unsuitable for infecting other cell systems such as endothelial cells. In this study a recent clinical isolate of HCMV was propagated through several passages in endothelial cells and was used to investigate the effect of HCMV infection of human umbilical vein endothelial cells (HUVEC) on IL-1 production and cell proliferation. Infection of HUVEC with the clinical isolate of HCMV (at multiplicity of infection 5:1) suppressed the production of IL-1 alpha (82%) and IL-1 beta (99%) at 5 h post infection; the levels returned to that of the control within 24h post infection. Ultraviolet inactivated (but not heat killed) virus produced similar suppression confirming that a thermolabile viral structural protein or intact virion were responsible for this suppression. Infection of HUVEC with the clinical isolate increased the number of these cells and the rate of their proliferation. An increase of infected HUVEC number under quiescent growth conditions continued as the infection progressed (6-10 days post infection), exhibiting, at 3 days post infection, 5 times the number of uninfected HUVEC (control) which did not tolerate the quiescent culture conditions for more than 4 days. Live virus is responsible for this increase because UV-inactivated virus did not maintain the proliferation of HUVEC. These studies suggest that while infection of HUVEC with a recent clinical isolate of HCMV suppressed the production of IL-1 at early hours after infection, it increased the proliferation of these cells at later stages of infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257291     DOI: 10.1007/bf01313770

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  26 in total

1.  Enhanced endothelial cytopathogenicity induced by a cytomegalovirus strain propagated in endothelial cells.

Authors:  W J Waldman; J M Sneddon; R E Stephens; W H Roberts
Journal:  J Med Virol       Date:  1989-08       Impact factor: 2.327

2.  Increased cytomegalovirus infection of human fibroblast and endothelial cells by electroporation.

Authors:  S Bidawid-Woodroffe; G Sullivan-Tailyour; P Roig-Farran; H M Garnett
Journal:  J Virol Methods       Date:  1992-07       Impact factor: 2.014

3.  The role of defective cytomegalovirus particles in the induction of host cell DNA synthesis.

Authors:  J M DeMarchi; A S Kaplan
Journal:  Virology       Date:  1977-10-01       Impact factor: 3.616

4.  Stimulation of ornithine decarboxylase by human cytomegalovirus.

Authors:  H C Isom
Journal:  J Gen Virol       Date:  1979-02       Impact factor: 3.891

5.  Virus infection of endothelial cells.

Authors:  H M Friedman; E J Macarak; R R MacGregor; J Wolfe; N A Kefalides
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

6.  Interleukin 1 is an autocrine regulator of human endothelial cell growth.

Authors:  F Cozzolino; M Torcia; D Aldinucci; M Ziche; F Almerigogna; D Bani; D M Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays.

Authors:  M N Bobrow; T D Harris; K J Shaughnessy; G J Litt
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

8.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  Cytomegalovirus alters the von Willebrand factor content in human endothelial cells.

Authors:  C A Bruggeman; W H Debie; A D Muller; B Schutte; M C van Dam-Mieras
Journal:  Thromb Haemost       Date:  1988-04-08       Impact factor: 5.249

10.  The immediate early genes of human cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-1 beta.

Authors:  J W Crump; L J Geist; P E Auron; A C Webb; M F Stinski; G W Hunninghake
Journal:  Am J Respir Cell Mol Biol       Date:  1992-06       Impact factor: 6.914

View more
  5 in total

1.  Transforming growth factor-beta induced by live or ultraviolet-inactivated equid herpes virus type-1 mediates immunosuppression in the horse.

Authors:  S Charan; K Palmer; P Chester; A R Mire-Sluis; A Meager; N Edington
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

2.  Early E-selectin, VCAM-1, ICAM-1, and late major histocompatibility complex antigen induction on human endothelial cells by flavivirus and comodulation of adhesion molecule expression by immune cytokines.

Authors:  J Shen; S S T-To; L Schrieber; N J King
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 3.  Novel Strategies to Combat CMV-Related Cardiovascular Disease.

Authors:  Elena Vasilieva; Sara Gianella; Michael L Freeman
Journal:  Pathog Immun       Date:  2020-09-20

4.  Membrane related effects in endothelial cells induced by human cytomegalovirus.

Authors:  A G van Geelen; M E Slobbe-van Drunen; A D Muller; C A Bruggeman; M C Van Dam-Mieras
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Human Cytomegalovirus Immediate Early 86-kDa Protein Blocks Transcription and Induces Degradation of the Immature Interleukin-1β Protein during Virion-Mediated Activation of the AIM2 Inflammasome.

Authors:  Sara Botto; Jinu Abraham; Nobuyo Mizuno; Kara Pryke; Bryan Gall; Igor Landais; Daniel N Streblow; Klaus J Fruh; Victor R DeFilippis
Journal:  mBio       Date:  2019-02-12       Impact factor: 7.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.